Group 1: Company Overview - Guangzhou Da'an Gene Co., Ltd. primarily focuses on product sales, with services accounting for a small proportion of its business [1] - The company has transitioned from ICL testing services, which were excluded from consolidated financial statements since October 2018 [1] - Da'an Gene has become a leading enterprise in the domestic molecular diagnostics industry after nearly 30 years of operation [2] Group 2: Industry Trends - The in vitro diagnostics (IVD) industry is evolving towards precision and personalization, driven by technological advancements and deeper disease understanding [2] - The company’s business encompasses various fields, including immunodiagnostics, biomedical technology, clinical applications, and food safety [2] Group 3: Competitive Advantages - Da'an Gene's competitive edge lies in its R&D capabilities, certification abilities, and product quality, along with unique product characteristics [2] - The company employs a direct sales model and has established long-term stable partnerships with hospitals and independent laboratories [2] Group 4: Investment Strategy - The company follows a "main business development + industry incubation" strategy, creating an industrial ecosystem to promote its main business and investment activities [2] - Da'an Gene has successfully incubated several companies, including Anjisi Medical Technology Co., Ltd., which went public on the Sci-Tech Innovation Board [2]

证券代码：002030 证券简称：达安基因 公告编号：2024-002 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司（以下简称"公司"）今日收到第二大股东广州 生物医药与健康产业投资有限公司（原称"广州生物工程中心有限公司"，以下 简称"第二大股东"）下发的《关于广州生物医药与健康产业投资有限公司名称 变更的函》（广健投函〔2024〕1 号），经广州市天河区行政审批局登记，公司第 二大股东名称由"广州生物工程中心有限公司"变更为"广州生物医药与健康产 业投资有限公司"。第二大股东于 2023 年 11 月 28 日完成了更名及相关工商登记 事项的变更手续，领取了新的《企业法人营业执照》，变更后的工商登记基本信 息如下： 本次公司第二大股东名称变更事项不涉及公司股权变动，不会导致公司控股 股东和实际控制人发生变化，不会对公司的生产经营构成影响。 特此公告。 1、名称：广州生物医药与健康产业投资有限公司 2、统一社会信用代码：91440101MA5D1RGK27 3、类型：有限责任公司（法人独资） 4、住所：广州市天河区龙口东路 34 ...

证券代码：002030 证券简称：达安基因 公告编号：2024-001 广州达安基因股份有限公司 特此公告。 广州达安基因股份有限公司 董 事 会 2024 年 1 月 2 日 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督 管理局颁发的医疗器械注册证一个，具体为： 医疗器械名称：人类免疫缺陷病毒 1 型（HIV-1）核酸测定试剂盒（PCR-荧 光探针法），注册证编号：国械注准 20233402071。有效期自批准之日起至 2028 年 12 月 27 日。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 ...

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2023013 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 参与单位名称及 信达证券 曹佳琳 人员姓名 时间 2023-12-20（上午10:15-上午11:30） 地点 广州市高新技术开发区科学城香山路19号（公司总部） 上市公司接待人 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 员姓名 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：公司在生化这方面增长快的原因主要是什么？ ...

附件： 注：左一为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Overview - The main business of the company is molecular products, with subsidiaries involved in immunology and biochemistry, covering the entire field of in vitro diagnostics [1] - The company has been actively obtaining various medical device certifications [1] Group 2: Financial Status - The company currently has sufficient cash flow to support daily operations and R&D investments, with no immediate plans for refinancing [2] Group 3: Market Opportunities - The pandemic has provided both opportunities and challenges, necessitating a focus on product innovation that offers cost-effective solutions for the public [2] - The company aims to diversify its product line through technological innovation to meet varying consumer needs and expand market share [2] Group 4: International Expansion - The company has exported PCR products to over 140 countries and has a complete product chain consisting of core raw materials, reagents, instruments, and supporting consumables [2] - Future plans include continued active exploration and expansion into overseas markets [2]

附件： 注：左一为公司董事会秘书张斌与调研人员合影留念。 ...

附件： 注：右一为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Overview - Da An Gene has focused on molecular diagnostic technology since its establishment, achieving significant research results and numerous product certifications [1] - The company provides reliable diagnostic solutions for clinical and related fields, with many products widely applied to safeguard public health [1] Group 2: Financial Performance - Da An Gene raised approximately 160 million during its IPO and has not conducted further financing since then [2] - Cumulative cash dividends exceed 4.5 billion since the company went public in 2004 [2] Group 3: Market Strategy - The company aims to strengthen collaborations with hospitals and medical institutions to better understand customer needs and provide more clinical diagnostic solutions [2] - Da An Gene will continue to invest in product research and development to enhance product cost-effectiveness and fulfill social responsibilities [2] Group 4: Competitive Advantage - Da An Gene has developed a complete, domestically leading nucleic acid testing technology supply chain, enabling rapid product development and large-scale production [2] - The company is committed to applying its products and technologies in clinical settings, distinguishing itself from other IVD companies [2]

附件： 注：左三为公司董事会秘书张斌与调研人员合影留念。 ...